封面
市場調查報告書
商品編碼
1298581

孤兒藥市場:2023-2028年全球行業趨勢、佔有率、規模、成長、機會和預測

Orphan Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

出版日期: | 出版商: IMARC | 英文 139 Pages | 商品交期: 2-3個工作天內

價格

2022年,全球孤兒藥市場規模達到1917億美元。展望未來,IMARC Group預計到2028年市場規模將達到3835億美元,在2023-2028年期間表現出12.02%的成長率(CAGR)。

孤兒藥指的是用於診斷、預防和治療罕見醫療疾病的醫藥產品。這些藥物的生產是為了滿足特定的公共衛生要求,通常市場有限,因為它們是為少數病人生產的。它們對眾多腫瘤、代謝、血液學、免疫學、傳染病和神經系統疾病有效。醫學上的疾病,如淋巴瘤、白血病、囊性纖維化、膠質瘤、胰腺癌、卵巢癌、多發性骨髓瘤和腎細胞癌等,往往是威脅生命的慢性疾病,是進行性的,是退化性的,是致殘性的,需要對其特殊症狀有效的特定治療方案。

孤兒藥市場趨勢:

癌症和其他罕見遺傳性疾病的發病率越來越高,這是推動市場成長的關鍵因素之一。製藥商正在開發創新的孤兒藥,為患者提供個性化的治療。群眾對孤兒藥好處的認知不斷提高,也推動了市場的發展。新的製藥廠家的出現和政府為抑制傳染病的傳播而實施的有利政策也促進了市場的成長。此外,各種產品創新,如生物孤兒藥的開發,正在成為其他成長的誘導因素。這些藥物可以治療疾病,如癌症,並扭轉對幹細胞造成的損害,這大大促進了它們的整體需求。其他因素,包括醫療基礎設施的改善,以及廣泛的研究和開發(R&D)活動,預計將進一步推動市場。

目錄

第一章:前言

第二章:範圍和方法

  • 研究的目標
  • 利益相關者
  • 數據來源
    • 主要來源
    • 二級來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第三章:執行摘要

第四章:簡介

  • 概述
  • 主要行業趨勢

第五章:全球孤兒藥市場

  • 市場概況
  • 市場表現
  • COVID-19的影響
  • 市場預測

第六章:按藥物類型分類的市場

  • 生物類
    • 市場趨勢
    • 市場預測
  • 非生物類
    • 市場趨勢
    • 市場預測

第7章:按疾病類型分類的市場

  • 腫瘤學
    • 市場趨勢
    • 市場預測
  • 血液學
    • 市場趨勢
    • 市場預測
  • 神經內科
    • 市場趨勢
    • 市場預測
  • 心血管科
    • 市場趨勢
    • 市場預測
  • 其他市場
    • 市場趨勢
    • 市場預測

第8章:按階段分類的市場

  • 第一階段
    • 市場趨勢
    • 市場預測
  • 第二階段
    • 市場趨勢
    • 市場預測
  • 第三階段
    • 市場趨勢
    • 市場預測
  • 第四階段
    • 市場趨勢
    • 市場預測

第九章:按最暢銷藥物分類的市場

  • Revlimid
    • 市場趨勢
    • 市場預測
  • 利妥昔單抗
    • 市場趨勢
    • 市場預測
  • 科帕酮
    • 市場趨勢
    • 市場預測
  • 歐狄沃
    • 市場趨勢
    • 市場預測
  • 凱特魯達
    • 市場趨勢
    • 市場預測
  • 英布羅維卡
    • 市場趨勢
    • 市場預測
  • 阿沃尼克斯
    • 市場趨勢
    • 市場預測
  • 森西帕
    • 市場趨勢
    • 市場預測
  • 潤百顏
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第十章:按配銷通路分類的市場

  • 醫院藥房
    • 市場趨勢
    • 市場預測
  • 零售藥店
    • 市場趨勢
    • 市場預測
  • 網路商店
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第十一章:按地區分類的市場

  • 北美洲
    • 美國
      • 市場趨勢
      • 市場預測
    • 加拿大
      • 市場趨勢
      • 市場預測
  • 亞太地區
    • 中國
      • 市場趨勢
      • 市場預測
    • 日本
      • 市場趨勢
      • 市場預測
    • 印度
      • 市場趨勢
      • 市場預測
    • 韓國
      • 市場趨勢
      • 市場預測
    • 澳大利亞
      • 市場趨勢
      • 市場預測
    • 印尼
      • 市場趨勢
      • 市場預測
    • 其他國家
      • 市場趨勢
      • 市場預測
  • 歐洲
    • 德國
      • 市場趨勢
      • 市場預測
    • 法國
      • 市場趨勢
      • 市場預測
    • 英國
      • 市場趨勢
      • 市場預測
    • 義大利
      • 市場趨勢
      • 市場預測
    • 西班牙
      • 市場趨勢
      • 市場預測
    • 俄羅斯
      • 市場趨勢
      • 市場預測
    • 其他國家
      • 市場趨勢
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場趨勢
      • 市場預測
    • 墨西哥
      • 市場趨勢
      • 市場預測
    • 其他國家
      • 市場趨勢
      • 市場預測
  • 中東和非洲
    • 市場趨勢
    • 按國家分類的市場
    • 市場預測

第十二章:SWOT分析

  • 概述
  • 優勢
  • 劣勢
  • 機會
  • 威脅

第十三章:價值鏈分析

第十四章:波特五力分析

  • 概述
  • 買方的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第十五章:價格分析

第16章:競爭格局

  • 市場結構
  • 主要參與者
  • 主要參與者的概況
    • AbbVie Inc.
    • Alexion Pharmaceuticals Inc.
    • Amgen Inc.
    • Biogen Inc.
    • Bristol Myers Squibb Company
    • F. Hoffmann-La Roche AG (Roche Holding AG)
    • Jazz Pharmaceuticals Plc
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd
Product Code: SR112023A2382

The global orphan drugs market size reached US$ 191.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 383.5 Billion by 2028, exhibiting a growth rate (CAGR) of 12.02% during 2023-2028.

Orphan drugs refer to pharmaceutical products used for the diagnosis, prevention and treatment of rare medical disorders. These drugs are manufactured to meet a specific public health requirement and usually have a limited market as they are produced for a small group of patients. They are effective against numerous oncological, metabolic, hematologic, immunologic, infectious and neurological diseases. Medical ailments, such as lymphoma, leukemia, cystic fibrosis, glioma, pancreatic cancer, ovarian cancer, multiple myeloma and renal cell carcinoma, are often life-threatening, chronic, progressive, degenerative and disabling and require specific treatment alternatives that are effective for their particular symptoms.

Orphan Drugs Market Trends:

The increasing prevalence of cancer and other rare genetic disorders is one of the key factors driving the growth of the market. Pharmaceutical manufacturers are developing innovative orphan drugs to provide personalized therapy to patients. The market is also being driven by increasing awareness among the masses regarding the benefits of orphan drugs. The emergence of new pharmaceutical drug manufacturers and the implementation of favorable government policies to inhibit the spread of contagious diseases are also contributing to the market growth. Additionally, various product innovations, such as the development of biological orphan drugs, are acting as other growth-inducing factors. These drugs can treat diseases, such as cancer, and reverse the damage caused to the stem cells, which is facilitating their overall demand significantly. Other factors, including improvements in the healthcare infrastructure, along with extensive research and development (R&D) activities, are expected to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global orphan drugs market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on drug type, disease type, phase, top selling drugs and distribution channel.

Breakup by Drug Type:

Biological

Non-Biological

Breakup by Disease Type:

Oncology

Hematology

Neurology

Cardiovascular

Others

Breakup by Phase:

Phase I

Phase II

Phase III

Phase IV

Breakup by Top Selling Drugs:

Revlimid

Rituxan

Copaxone

Opdivo

Keytruda

Imbruvica

Avonex

Sensipar

Soliris

Others

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Stores

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being AbbVie Inc., Alexion Pharmaceuticals Inc., Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), Jazz Pharmaceuticals Plc, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

1. What was the size of the global orphan drugs market in 2022?

2. What is the expected growth rate of the global orphan drugs market during 2023-2028?

3. What are the key factors driving the global orphan drugs market?

4. What has been the impact of COVID-19 on the global orphan drugs market?

5. What is the breakup of the global orphan drugs market based on the drug type?

6. What is the breakup of the global orphan drugs market based on the disease type?

7. What is the breakup of the global orphan drugs market based on top selling drugs?

8. What is the breakup of the global orphan drugs market based on the distribution channel?

9. What are the key regions in the global orphan drugs market?

10. Who are the key players/companies in the global orphan drugs market?

Table of Contents

1   Preface

2   Scope and Methodology 

  • 2.1  Objectives of the Study
  • 2.2  Stakeholders
  • 2.3  Data Sources
    • 2.3.1  Primary Sources
    • 2.3.2  Secondary Sources
  • 2.4  Market Estimation
    • 2.4.1  Bottom-Up Approach
    • 2.4.2  Top-Down Approach
  • 2.5  Forecasting Methodology

3   Executive Summary

4   Introduction

  • 4.1  Overview
  • 4.2  Key Industry Trends

5   Global Orphan Drugs Market

  • 5.1  Market Overview
  • 5.2  Market Performance
  • 5.3  Impact of COVID-19
  • 5.4  Market Forecast

6   Market Breakup by Drug Type

  • 6.1  Biological
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2  Non-Biological
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7   Market Breakup by Disease Type

  • 7.1  Oncology
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2  Hematology
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3  Neurology
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4  Cardiovascular
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5  Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8   Market Breakup by Phase

  • 8.1  Phase I
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2  Phase II
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3  Phase III
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4  Phase IV
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9   Market Breakup by Top Selling Drugs

  • 9.1  Revlimid
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2  Rituxan
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3  Copaxone
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4  Opdivo
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5  Keytruda
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast
  • 9.6  Imbruvica
    • 9.6.1 Market Trends
    • 9.6.2 Market Forecast
  • 9.7  Avonex
    • 9.7.1 Market Trends
    • 9.7.2 Market Forecast
  • 9.8  Sensipar
    • 9.8.1 Market Trends
    • 9.8.2 Market Forecast
  • 9.9  Soliris
    • 9.9.1 Market Trends
    • 9.9.2 Market Forecast
  • 9.10  Others
    • 9.10.1 Market Trends
    • 9.10.2 Market Forecast

10  Market Breakup by Distribution Channel

  • 10.1  Hospital Pharmacies
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2  Retail Pharmacies
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3  Online Stores
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4  Others
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast

11  Market Breakup by Region

  • 11.1  North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2  Asia Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3  Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4  Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5  Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12  SWOT Analysis

  • 12.1  Overview
  • 12.2  Strengths
  • 12.3  Weaknesses
  • 12.4  Opportunities
  • 12.5  Threats

13  Value Chain Analysis

14  Porters Five Forces Analysis

  • 14.1  Overview
  • 14.2  Bargaining Power of Buyers
  • 14.3  Bargaining Power of Suppliers
  • 14.4  Degree of Competition
  • 14.5  Threat of New Entrants
  • 14.6  Threat of Substitutes

15  Price Analysis

16  Competitive Landscape

  • 16.1  Market Structure
  • 16.2  Key Players
  • 16.3  Profiles of Key Players
    • 16.3.1  AbbVie Inc.
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio 
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2  Alexion Pharmaceuticals Inc.
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio 
      • 16.3.2.3 Financials
      • 16.3.2.4 SWOT Analysis
    • 16.3.3  Amgen Inc.
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio 
      • 16.3.3.3 Financials
      • 16.3.3.4 SWOT Analysis
    • 16.3.4  Biogen Inc.
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio 
      • 16.3.4.3 Financials
      • 16.3.4.4 SWOT Analysis
    • 16.3.5  Bristol Myers Squibb Company
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio 
      • 16.3.5.3 Financials
      • 16.3.5.4 SWOT Analysis
    • 16.3.6  F. Hoffmann-La Roche AG (Roche Holding AG)
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio 
      • 16.3.6.3 SWOT Analysis
    • 16.3.7  Jazz Pharmaceuticals Plc
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio 
      • 16.3.7.3 Financials
      • 16.3.7.4 SWOT Analysis
    • 16.3.8  Johnson & Johnson 
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
      • 16.3.8.4 SWOT Analysis
    • 16.3.9  Merck & Co. Inc.
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio 
      • 16.3.9.3 Financials
      • 16.3.9.4 SWOT Analysis
    • 16.3.10  Novartis AG
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio 
      • 16.3.10.3 Financials
      • 16.3.10.4 SWOT Analysis
    • 16.3.11  Pfizer Inc.
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio 
      • 16.3.11.3 Financials
      • 16.3.11.4 SWOT Analysis
    • 16.3.12  Sanofi S.A. 
      • 16.3.12.1 Company Overview
      • 16.3.12.2 Product Portfolio 
      • 16.3.12.3 Financials
      • 16.3.12.4 SWOT Analysis
    • 16.3.13  Takeda Pharmaceutical Company Limited 
      • 16.3.13.1 Company Overview
      • 16.3.13.2 Product Portfolio 
      • 16.3.13.3 Financials
      • 16.3.13.4 SWOT Analysis
    • 16.3.14  Teva Pharmaceutical Industries Ltd
      • 16.3.14.1 Company Overview
      • 16.3.14.2 Product Portfolio 
      • 16.3.14.3 Financials
      • 16.3.14.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Orphan Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Orphan Drugs Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Orphan Drugs Market: Breakup by Drug Type (in %), 2022
  • Figure 4: Global: Orphan Drugs Market: Breakup by Disease Type (in %), 2022
  • Figure 5: Global: Orphan Drugs Market: Breakup by Phase (in %), 2022
  • Figure 6: Global: Orphan Drugs Market: Breakup by Top Selling Drugs (in %), 2022
  • Figure 7: Global: Orphan Drugs Market: Breakup by Distribution Channel (in %), 2022
  • Figure 8: Global: Orphan Drugs Market: Breakup by Region (in %), 2022
  • Figure 9: Global: Orphan Drugs Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 10: Global: Orphan Drugs (Biological) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Orphan Drugs (Biological) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Orphan Drugs (Non-Biological) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Orphan Drugs (Non-Biological) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Orphan Drugs (Oncology) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Orphan Drugs (Oncology) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Orphan Drugs (Hematology) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Orphan Drugs (Hematology) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Orphan Drugs (Neurology) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Orphan Drugs (Neurology) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Orphan Drugs (Cardiovascular) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Orphan Drugs (Cardiovascular) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Orphan Drugs (Other Disease Types) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Orphan Drugs (Other Disease Types) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Orphan Drugs (Phase I) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Orphan Drugs (Phase I) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Global: Orphan Drugs (Phase II) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Global: Orphan Drugs (Phase II) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: Global: Orphan Drugs (Phase III) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: Global: Orphan Drugs (Phase III) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: Global: Orphan Drugs (Phase IV) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: Global: Orphan Drugs (Phase IV) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Global: Orphan Drugs (Revlimid) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Global: Orphan Drugs (Revlimid) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: Global: Orphan Drugs (Rituxan) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: Global: Orphan Drugs (Rituxan) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: Global: Orphan Drugs (Copaxone) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: Global: Orphan Drugs (Copaxone) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Global: Orphan Drugs (Opdivo) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Global: Orphan Drugs (Opdivo) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: Global: Orphan Drugs (Keytruda) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: Global: Orphan Drugs (Keytruda) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: Global: Orphan Drugs (Imbruvica) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: Global: Orphan Drugs (Imbruvica) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Global: Orphan Drugs (Avonex) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Global: Orphan Drugs (Avonex) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: Global: Orphan Drugs (Sensipar) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: Global: Orphan Drugs (Sensipar) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: Global: Orphan Drugs (Soliris) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: Global: Orphan Drugs (Soliris) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: Global: Orphan Drugs (Other Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: Global: Orphan Drugs (Other Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: Global: Orphan Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: Global: Orphan Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: Global: Orphan Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: Global: Orphan Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Global: Orphan Drugs (Online Stores) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Global: Orphan Drugs (Online Stores) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Global: Orphan Drugs (Other Distribution Channels) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Global: Orphan Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: North America: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: North America: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: United States: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: United States: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Canada: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Canada: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Asia Pacific: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Asia Pacific: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: China: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: China: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Japan: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Japan: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: India: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: India: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 74: South Korea: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 75: South Korea: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 76: Australia: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 77: Australia: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 78: Indonesia: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 79: Indonesia: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 80: Others: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 81: Others: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 82: Europe: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 83: Europe: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 84: Germany: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 85: Germany: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 86: France: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 87: France: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 88: United Kingdom: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 89: United Kingdom: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 90: Italy: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 91: Italy: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 92: Spain: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 93: Spain: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 94: Russia: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 95: Russia: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 96: Others: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 97: Others: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 98: Latin America: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 99: Latin America: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 100: Brazil: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 101: Brazil: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 102: Mexico: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 103: Mexico: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 104: Others: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 105: Others: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 106: Middle East and Africa: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 107: Middle East and Africa: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 108: Global: Orphan Drugs Industry: SWOT Analysis
  • Figure 109: Global: Orphan Drugs Industry: Value Chain Analysis
  • Figure 110: Global: Orphan Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Orphan Drugs Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Orphan Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2023-2028
  • Table 3: Global: Orphan Drugs Market Forecast: Breakup by Disease Type (in Million US$), 2023-2028
  • Table 4: Global: Orphan Drugs Market Forecast: Breakup by Phase (in Million US$), 2023-2028
  • Table 5: Global: Orphan Drugs Market Forecast: Breakup by Top Selling Drugs (in Million US$), 2023-2028
  • Table 6: Global: Orphan Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
  • Table 7: Global: Orphan Drugs Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 8: Global: Orphan Drugs Market Structure
  • Table 9: Global: Orphan Drugs Market: Key Players